DiamiR

DiamiR is a private, pre-revenue diagnostics company pioneering a platform based on brain-enriched microRNA biomarkers detectable in blood plasma. Its lead program, CogniMIR™, targets the early detection of mild cognitive impairment and Alzheimer's disease, with additional programs in neurodevelopmental disorders and healthy aging. The company aims to address critical unmet needs in screening, differential diagnosis, and therapy monitoring through collaborations with academia and industry, supported by a growing intellectual property portfolio.

Analysis of brain-enriched microRNA biomarkers in blood plasma. The platform leverages microRNAs that are enriched in brain regions and synapses, can cross the blood-brain barrier, and whose levels in plasma change in response to neurological disease and synaptic health.

DiamiR competes in the rapidly evolving field of blood-based biomarkers for neurology. Competitors include large diagnostic firms (e.g., Quest, Roche) and biotech companies focusing on proteins like phosphorylated tau (p-tau181, p-tau217) and neurofilament light chain (NfL). DiamiR's differentiation lies in its focus on brain-enriched microRNAs as an alternative biomarker class potentially offering unique insights into synaptic health.